Table 1 Comparisons of clinical characteristics

Mean age

30(22–57)

31(21–54)

0.25

Median gravidity

2(1–10)

2(1–8)

0.17

Median parity

1(1–9)

1(1–4)

0.56

Previous hydatidiform mole or invasive mole

21(17 %)

27(18 %)

0.82

Median interval from index pregnancy, months

7(0–216)

13(0–348)

0.002

Interval from index pregnancy <4 mo

47(38 %)

31(21 %)

0.002

Interval from index pregnancy >12 mo

36(29 %)

75(50 %)

0.000

Mean pretreatment β-hCG mIU/ml

119692 (6.5-3120000)

103554 (negative-2876010)

0.67

Pretreatment >400,000 β-hCG mIU/ml

5(4 %)

10(7 %)

0.34

Metastatic disease

98(80 %)

128(86 %)

0.17

Metastatic sites ≥2

38(31 %)

39(26 %)

0.39

Symptoms

   Abnormal uterine bleeding

91(74 %)

111(74 %)

0.92

   Hemoptysis

14(11 %)

13(9 %)

0.47

   Central neural system symptoms

12(10 %)

4(3 %)

0.17

   Fetal death or stillbirth

3(2 %)

11(7 %)

0.07

Resistance to multiagent chemotherapy

49(40 %)

72(48 %)

0.16

Mean chemotherapy courses

8.5(1–27)

7.5(1–26)

0.44

Numbers of surgeries

75(61 %)

88(59 %)

0.75

Mean FIGO score

9.2(2–19)

9.4(2–22)

0.59

FIGO score >12

25(20 %)

31(21 %)

0.92

FIGO stage

   I

24(20 %)

22(15 %)

0.30

   II

9(7 %)

0(0 %)

n/a^a

   III

66(54 %)

95(64 %)

0.09

   IV

24(19 %)

32(21 %)

0.69